<DOC>
	<DOCNO>NCT00003248</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop cancer cell divide stop grow die . Monoclonal antibody locate cancer cell either kill deliver cancer-killing substance without harm normal cell . Combining monoclonal antibody therapy chemotherapy may kill cancer cell . PURPOSE : Randomized phase II trial compare effectiveness fludarabine give without monoclonal antibody therapy follow monoclonal antibody therapy alone treat patient untreated B-cell chronic lymphocytic leukemia .</brief_summary>
	<brief_title>Fludarabine Monoclonal Antibody Therapy Treating Patients With Untreated B-cell Chronic Lymphocytic Leukemia</brief_title>
	<detailed_description>OBJECTIVES : I . Determine response rate toxicity profile concurrent consolidative chimeric anti-CD20 monoclonal antibody IDEC-C2B8 ( rituximab ) therapy compare consolidative rituximab therapy patient chronic lymphocytic leukemia treat fludarabine . II . Assess complete response ( CR ) rate patient receive concurrent therapy rituximab fludarabine . III . Assess frequency conversion partial response ( PR ) CR stable disease either PR CR patient receive consolidative therapy rituximab . IV . Follow effect rituximab fludarabine immunologic marker CD4 , CD8 , IgG , IgA , IgM . V. Assess progression-free overall survival patient . OUTLINE : This randomize study . Patients stratify accord stage ( I II v III IV ) . Patients assign 1 2 treatment arm . Arm I consist fludarabine chimeric anti-CD20 monoclonal antibody IDEC-C2B8 ( rituximab ) induction , arm II consist fludarabine induction . Arm I : Rituximab administer IV 4 hour day 1 , day 3 , 1 hour day 5 week 1 . Subsequent dos give 1 hour day 1 every 4 week total 6 course . Fludarabine IV administer 10-30 minute daily 5 day week 1 , 5 , 9 , 13 , 17 , 21 total 6 course . Following sixth course fludarabine , patient undergo clinical staging observe additional 2 month , undergo repeat clinical staging , include bone marrow aspiration . Patients achieve complete partial response stable disease proceed consolidation therapy consist weekly intravenous infusion rituximab weekly 4 week . Arm II ( Fludarabine Induction ) : Patients receive fludarabine IV 10-30 minute daily 5 day week 1 , 5 , 9 , 13 , 17 , 21 total 6 course . Patients proceed arm I . Patients follow every 3 month 1 year , every 6 month thereafter . PROJECTED ACCRUAL : A maximum 100 patient accrue study within 12 month .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<mesh_term>Vidarabine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically proven Bcell chronic lymphocytic leukemia Stage I II evidence active disease define : Massive progressive splenomegaly and/or lymphadenopathy Weight loss great 10 % within 6 month CALGB grade 2 3 fatigue Fevers great 100.5 C night sweat 2 week evidence infection Progressive lymphocytosis Stage III IV Patient registration CALGB 9665 require PATIENT CHARACTERISTICS : Age : 18 Performance status : CALGB 03 Life expectancy : Not specify Hematopoietic : Not specify Hepatic : Not specify Renal : Creatinine great 1.5 time upper limit normal Other : No medical condition require chronic use oral corticosteroid Direct antiglobulin test direct Coombs test negative Not pregnant Effective contraception require fertile patient PRIOR CONCURRENT THERAPY : Biologic : No prior biologic therapy disease No concurrent erythropoietin Chemotherapy : No concurrent chemotherapy No prior chemotherapy disease Endocrine : No concurrent chronic oral corticosteroid No prior corticosteroid autoimmune complication develop since diagnosis No concurrent hormone therapy disease related condition No concurrent dexamethasone corticosteroidbased antiemetic Radiotherapy : No concurrent palliative radiotherapy Surgery : Not specify Other : No prophylactic therapy viral , bacterial , fungal infection</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>stage I chronic lymphocytic leukemia</keyword>
	<keyword>stage II chronic lymphocytic leukemia</keyword>
	<keyword>stage III chronic lymphocytic leukemia</keyword>
	<keyword>stage IV chronic lymphocytic leukemia</keyword>
	<keyword>B-cell chronic lymphocytic leukemia</keyword>
</DOC>